EU Court Backs Astra Antitrust Fine Over Patent Abuse

Law360, New York (July 1, 2010, 1:40 PM EDT) -- A European court affirmed on Thursday a 2005 European Commission decision that AstraZeneca PLC abused its market dominance and the patent system in order to block generic competitors for its blockbuster ulcer drug Losec, but trimmed €7.5 million ($9.4 million) from the drugmaker's fine for hindering parallel imports.

The General Court of the European Union upheld the bulk of the European Commission's decision and €60 million fine against the Anglo-Swedish company, agreeing that AstraZeneca had misled national patent offices in order to extend its patent protections...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.